V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Champions Oncology Executive Compensation (FY26)

CSBR · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
Robert Brainin
Latest say-on-pay support
=
October 14, 2026
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Champions Oncology brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
New filing — October 16, 2026, data updatedData as of October 22, 2026Latest filing (8-K): October 16, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Champions Oncology brief$1,500Get the executive brief
Velarion Member, one year
115 figures on this page: 104 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Ronnie Morris → Robert Brainin

Frequently asked questions

Answers drawn from the data on this page.
Who is Champions Oncology's chief executive and what were they paid?
Total compensation for Robert Brainin, Chief Executive Officer, came to $3,567,022 in fiscal 2026.
What was Champions Oncology's say-on-pay result?
Shareholders recorded 99.7% support for the say-on-pay proposal at the meeting held October 14, 2026 for fiscal 2026.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ronnie Morris
Chief Executive Officer
◇◇—————◇
David Miller
Chief Financial Officer
◇◇—◇———◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ronnie Morris
Chief Executive Officer
◇◇—————◇
David Miller
Chief Financial Officer
◇◇—◇———◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brady Davis
President
◇◇—◇———◇
Ronnie Morris
Chief Executive Officer
◇——————◇
David Miller
Chief Financial Officer
◇——————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ronnie Morris
Chief Executive Officer
◇◇—————◇
David Miller
Chief Financial Officer
◇◇—◇———◇
Brady Davis
President
◇——————◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Brainin
Chief Executive Officer
◇——◇———◇
David Miller
Chief Financial Officer
◇◇—◇———◇
Ronnie Morris
Chief Executive Officer
◇——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David MillerOption——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert BraininOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
David MillerOption◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joel Ackerman
——◇———◇
Daniel Mendelson
◇—◇———◇
Scott R. Tobin
——◇———◇
Philip Breitfeld
◇—◇———◇
David Sidransky
◇—◇———◇
Ronnie Morris
Board chair
◇—————◇
Robert Brainin
◇—◇———◇
Brian Alexander
——◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2026October 14, 2026=◇◇◇
2025October 16, 2025=◇◇◇
2024October 14, 2024=◇◇◇
2023October 19, 2023=◇◇◇
2022October 20, 2022=◇◇◇
2021October 20, 2021=◇◇◇
2020October 21, 2020=◇◇◇
2019October 16, 2019=◇◇◇
2018October 16, 2018=◇◇◇
2017October 16, 2017=◇◇◇
2016October 13, 2016=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Brainin (Chief Executive Officer), FY2026 total compensation $3,567,022 (base salary $346,154) [exec_comp, SEC accession 0001628280-26-059373, filed 2026-08-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Champions Oncology files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Champions Oncology disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Champions Oncology's disclosed peer group is defensible, who names Champions Oncology back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
115 figures on this page: 104 cited to the filing that reported them, 11 calculated from figures it prints.
104 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001628280-26-066087
  2. 0001628280-26-059373
  3. 0001628280-25-045241
  4. 0000771856-25-000009
    Summary Compensation Table · THE NON-BINDING ADVISORY RESOLUTION RELATING TO THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
  5. 0001628280-24-042780
  6. 0001628280-23-034703
  7. 0001628280-23-030752
  8. 0001628280-22-026738
  9. 0001628280-21-020321
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001628280-20-014644
  11. 0001628280-19-012310
  12. 0001628280-18-012569
  13. 0001628280-17-009909
  14. 0001628280-16-020070
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Champions Oncology executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/CSBR (accessed 2026).
Short form: data: Velarion

The Champions Oncology brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Champions Oncology and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy